IM Individual ≥12 yr w/ or w/o prior vaccination 1 dose (0.5 mL), administered at least 3 mth after the most recent dose of COVID-19 vaccine. Individual ≥65 yr 1 dose. 1 additional dose may be administered at least 3 mth after the most recent dose of COVID-19 vaccine. Immunocompromised ≥12 yr w/ or w/o prior vaccination 1 dose (0.5 mL). Additional age-appropriate dose(s) may be administered in severely immunocompromised at least 2 mth following the most recent dose of a COVID-19 vaccine.
Do not administer intravascularly, SC or intradermally. Should not be given to those who have experienced anaphylaxis to a prior dose of Spikevax (original). Increased risk for myocarditis & pericarditis following vaccination w/ Spikevax. Postpone vaccination in individuals suffering from acute severe febrile illness or acute infection. Caution in individuals receiving anticoagulant therapy or those w/ thrombocytopenia or any coagulation disorder. Reports of capillary leak syndrome flare-ups in the 1st days after vaccination w/ Spikevax (original). Efficacy has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy & may be lower in immunocompromised individuals. Not intended for childn <12 yr.
Sign Out
b7ae70f3-6b15-4935-b5f9-b109011d2bd1.GIF)
